Cholesterol Management – Understanding the 2018 Guideline- Pharmacist

  Price  

  Credits  

This product is currently out of stock and unavailable.


Format
Cardiovascular disease (CVD), which includes high blood pressure, stroke, heart failure, and coronary heart disease, is prevalent and costly. Coronary heart disease is the most common form, accounting for 43% of all deaths attributed to CVD. The underlying pathophysiology of CVD is atherosclerosis; hence the term atherosclerotic cardiovascular disease (ASCVD). Risk factor management and treatment are essential to prevent CVD progression, cardiovascular events, and costly healthcare. It is important for both prescribers and pharmacists to educate patients about a heart healthy lifestyle and promote adherence to drug therapy to prevent disease progression and lower the costs associated with CVD. In November 2018, the American College of Cardiology and the American Heart Association (ACC/AHA) cholesterol guideline was published online. The writing committee included physicians from several specialty areas, pharmacists, a nurse practitioner, a physician assistant, and a layperson. In addition to the ACC/AHA, the writing committee included representatives from 10 other national organizations. The guideline provides an evidence-based and patient-centered approach to the assessment and treatment of ASCVD. The 2018 guideline builds on many of the concepts introduced in the 2013 ACC/AHA cholesterol guideline, including the emphasis on using a high or moderate-intensity statin as first-line therapy based on patient risk, the use of the 10-year ASCVD risk estimator for certain patients, measuring lipids to monitor response to therapy and adherence, and the patient-clinician discussion...

OR

Subscribe and Save. Get access to this course PLUS the Rx Resource Library!

Explore Our Subscription Options

Course Information

Target Audience

Pharmacist

Author
Heesoo Kim
PharmD
Knowledge Level

General Overview

This activity will apply to a broad range of learning needs/pharmacy settings. It may include common disease state/therapy overivews and/or general pharmacy needs such as medication errors, immunizations, or law topics.

Learning Objectives

  • Compare and contrast the 2013 and 2018 ACC/AHA cholesterol guidelines; list key similarities and differences.
  • Summarize the terms "primary prevention" and "secondary prevention" as applied to cardiovascular disease. Describe the risk assessment calculators that should be used for each patient to calculate the risk of developing ASCVD.
  • List the 4 statin benefit groups; recognize which patients would be placed in each group. Recommend a statin regimen based on the group a patient is placed in and/or whether they are part of a special population at risk for ASCVD.
  • Discuss guideline implementation strategies and provide patient counseling tips about statins and related muscle effects, liver dysfunction, and new-onset diabetes.

Course Accreditation

  • Activity Type:
    Knowledge
  • CE Broker
    878472
  • Universal Activity Number:
    Pharmacist : 0798-0000-21-206-H01-P
PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

Credit for this program is issued by passing the final test hosted at www.RxConsultant.com with a score of 70% or higher.

Technology Requirements

  • Hardware Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
  • Software Requirements
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
  • Network Requirements
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.